摘要
目的探究血液灌流(HP)联合血液透析(HD)对维持性血液透析(MHD)患者的β_(2)微球蛋白(β_(2)-MG)清除及生活质量的影响。方法选取2019年3—6月本院收治的36例MHD患者作为研究对象,根据治疗方案的不同分为观察组(n=17)与对照组(n=19)。对照组给予单纯HD治疗,观察组给予HP联合HD治疗。比较两组治疗前后β_(2)-MG水平及生活质量评分,随访治疗效果及并发症发生率。结果治疗前,两组β_(2)-MG水平比较差异无统计学意义;治疗后,观察组β_(2)-MG水平均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组各项生活质量评分比较差异无统计学意义;治疗后,观察组生活质量评分高于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为94.12%,明显高于对照组的47.37%,差异有统计学意义(P<0.05)。两组并发症发生率比较差异无统计学意义。结论HP联合HD治疗MHD效果显著,可明显改善患者β_(2)-MG水平,利于提升生活质量,且具有较高的安全性,值得临床推广应用。
Objective To explore the effect of hemoperfusion(HP)combined with hemodialysis(HD)onβ_(2) microglobulin(β_(2)-MG)clearance and quality of life in maintenance hemodialysis(MHD)patients.Methods 36 MHD patients admitted to our hospital from March to June 2019 were selected as the research subjects,and they were divided into observation group(n=17)and control group(n=19)according to different treatment plans.The control group was given HD treatment alone,and the observation group was given HP combined HD treatment.Theβ_(2)-MG and quality of life scores,follow-up treatment effects and complication rates were compared between the two groups before and after treatment.Results Before treatment,there was no statistically significant difference inβ_(2)-MG levels between the two groups;after treatment,theβ_(2)-MG level of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the quality of life scores between the two groups;after treatment,the quality of life scores in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was 94.12%,which was significantly higher than the 47.37%of the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of complications between the two groups.Conclusion HP combined with HD has significant effect in the treatment of MHD,which can significantly improve theβ_(2)-MG level of patients,which is beneficial to improve the quality of life,and has high safety,it is worthy of clinical application.
作者
江李红
胡蓓君
刘硕
张帅
漆映辉
JIANG Lihong;HU Beijun;LIU Shuo;ZHANG Shuai;QI Yinghui(Department of Nephrology,Shanghai Huangpu District Cancer Center,Shanghai,201126,China)
出处
《当代医学》
2021年第35期48-50,共3页
Contemporary Medicine
基金
上海市黄浦区卫计委支持项目(HKM201828)。
